| Drug Name | Benlysta (Belimumab) |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Rheumatology
|
| Risk |
Risk of serious Depression and/ or Suicidal ideation or Behavior or self-injury. Post Marketing Reports, One Fatal, of Progressive Multifocal Leukoencephalopathy (PML) in Patients with Systemic Lupus Erythematosus (SLE) |
| Dear Healthcare provider letter DHPC |
|